Theravance Biopharma, Inc. (TBPH)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Theravance Biopharma, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Theravance Biopharma, Inc. (TBPH) has returned -13.25% so far this year and 81.75% over the past 12 months. Over the last ten years, TBPH has returned -1.91% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since May 16, 2014, TBPH's average daily return is +0.04%, while the average monthly return is +0.78%. At this rate, your investment would double in approximately 7.4 years.

Historically, 47% of months were positive and 53% were negative. The best month was Jun 2014 with a return of +48.1%, while the worst month was Aug 2021 at -36.1%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 7 months.

On a daily basis, TBPH closed higher 50% of trading days. The best single day was Nov 11, 2025 with a return of +22.7%, while the worst single day was Aug 24, 2021 at -34.8%.

Theravance Biopharma, Inc. has an annualized alpha of -0.15%, beta of 0.88, and R² of 0.09 versus S&P 500 Index. Calculated based on daily prices since May 19, 2014.

• This stock participated in 98.59% of S&P 500 Index downside but only 41.54% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.09 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

TBPH ranks 82 for risk / return — in the top 82% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Theravance Biopharma, Inc. (TBPH) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Theravance Biopharma, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Theravance Biopharma, Inc. was 84.09%, occurring on Sep 15, 2021. The portfolio has not yet recovered.

The current Theravance Biopharma, Inc. drawdown is 61.87%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Theravance Biopharma, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Theravance Biopharma, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.